Secretory Leukocyte Proteinase Inhibitor Protects Acute Kidney Injury Through Immune and Non-Immune Pathways

Area of Science:

• Nephrology
• Immunology
• Molecular Biology

Background:

• Acute kidney injury (AKI) is a critical clinical condition characterized by rapid loss of kidney function.
• Understanding the protective mechanisms against AKI is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the protective mechanism of Secretory Leukocyte Proteinase Inhibitor (SLPI) against acute kidney injury (AKI).
• To assess the direct effects of SLPI on renal epithelial cells and its impact on inflammatory pathways.

Main Methods:

• In vivo studies using ischemia-reperfusion and gentamicin-induced AKI models in animals.
• In vitro studies using human renal epithelial HK-2 cells under serum starvation or tacrolimus treatment.
• Analysis of plasma creatinine, blood urea nitrogen, tissue myeloperoxidase, gene expression, apoptosis, proliferation, and migration.

Main Results:

• SLPI administration reduced markers of kidney damage, inflammation, and necrosis in vivo.
• SLPI protected renal epithelial cells from apoptosis and promoted their proliferation and migration in vitro.
• SLPI modulated inflammatory and non-inflammatory gene expression pathways in renal cells.

Conclusions:

• SLPI exhibits nephroprotective effects in AKI through mechanisms involving both immune cells and direct targeting of tubular epithelial cells.
• SLPI may serve as a potential therapeutic agent for mitigating kidney damage in AKI.